Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Incyte Corp
(NQ:
INCY
)
51.68
+0.50 (+0.98%)
Streaming Delayed Price
Updated: 3:12 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
779,379
Open
50.99
Bid (Size)
51.67 (1)
Ask (Size)
51.69 (2)
Prev. Close
51.18
Today's Range
50.87 - 51.85
52wk Range
50.27 - 75.74
Shares Outstanding
222,430,635
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Don't overlook NASDAQ:INCY—a stock with solid growth prospects and a reasonable valuation.
Today 8:30 EDT
In the world of growth stocks, NASDAQ:INCY shines as a value proposition.
Via
Chartmill
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
April 23, 2024
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.
Via
Benzinga
Performance
YTD
-21.04%
-21.04%
1 Month
-8.61%
-8.61%
3 Month
-15.17%
-15.17%
6 Month
-4.77%
-4.77%
1 Year
-29.72%
-29.72%
More News
Read More
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
April 23, 2024
Via
Benzinga
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
April 23, 2024
From
Incyte and Escient Pharmaceuticals
Via
Business Wire
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
April 17, 2024
Via
Chartmill
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
April 05, 2024
Via
Chartmill
NASDAQ:INCY, a growth stock which is not overvalued.
March 15, 2024
Via
Chartmill
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
March 12, 2024
Via
Benzinga
Incyte to Report First Quarter Financial Results
April 11, 2024
From
Incyte
Via
Business Wire
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
Via
Talk Markets
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
April 01, 2024
From
Incyte
Via
Business Wire
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
March 04, 2024
Via
Chartmill
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Incyte
Via
Business Wire
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
March 26, 2024
Via
Chartmill
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
March 11, 2024
Via
InvestorPlace
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
March 10, 2024
From
Incyte Corporation
Via
Business Wire
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
March 10, 2024
From
Incyte
Via
Business Wire
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
March 07, 2024
Via
InvestorPlace
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 04, 2024
From
Incyte
Via
Business Wire
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
February 29, 2024
From
Incyte
Via
Business Wire
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
February 27, 2024
From
Incyte
Via
Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
February 26, 2024
Via
InvestorPlace
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
February 22, 2024
Via
Chartmill
Exit Now! 3 Biotech Stocks to Sell in February 2024
February 21, 2024
Via
InvestorPlace
Incyte to Present at Upcoming Investor Conference
February 15, 2024
From
Incyte
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.